When was Rigel founded?

Rigel was founded in 1996 and raised its 1st funding round 23 years after it was founded.

Where is Rigel located?

Rigel is headquartered in San Francisco, United States. It is registered at S. San Francisco, California.

How many employees does Rigel have?

As of Sep 30, 2026, the latest employee count at Rigel is 292.

Is Rigel a funded company?

Rigel is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Oct 02, 2019.

When was the latest funding round of Rigel?

Rigel's latest funding was a $***** Grant (prize money) round on Jan 29, 2021, with participation from 1 investor.

What is the annual revenue of Rigel?

Annual revenue of Rigel is between $100M and $500M as on Dec 31, 2025

Where does Rigel rank among its competitors?

Rigel ranks 31st amongst 998 active competitors, of which 300 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was X4 Pharmaceuticals, which secured $85M in Aug, 2025.

Who are the top competitors of Rigel?

Rigel's top competitors include BeiGene, Biogen and X4 Pharmaceuticals. Among them, X4 Pharmaceuticals secured the most recent funding round in August, 2025.

Rigel - 2026 Company Profile, Funding, Competitors & Financials

Rigel is a public company based in San Francisco (United States), founded in 1996. It operates as a Developer of drugs for hematologic disorders, cancer, and rare immune disease. Rigel has raised an undisclosed amount in funding. The company has 998 active competitors, including 300 funded and 250 that have exited. Its top competitors include companies like BeiGene, Biogen and X4 Pharmaceuticals.

Company Details

Developer of drugs for hematologic disorders, cancer, and rare immune disease. The product TAVALISSE is the oral spleen tyrosine kinase inhibitor for the treatment of immune thrombocytopenia which is a rare autoimmune disease. Other candidates include Fostamatinib for covid-19, Bemcentenib for cancer, AZD0449 for asthma, R835, and R552 for immune disease.

Website: www.rigel.com/
Social
Registered Address: S. San Francisco, California

Key Metrics

Founded Year

1996

Location

San Francisco, United States

Stage

Public

Latest Funding Round

Grant (prize money), Jan 29, 2021, $*****

Investors

MidCap Financial & 7 more

Ranked

31^st among 998 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

292 as on Sep 30, 2026

Similar Companies

BeiGene & 815 more

Exit Details

Public

View Rigel's full profile

Rigel is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Rigel Pharmaceuticals, Inc. CIN: 39.995.548/0001-54 , Brazil, Active	Dec 02, 2020	-	-	-
Rigel Pharmaceuticals Inc CIN: 1034842 , United States, Active	Jun 13, 1996	$100M - $500M (As on Dec 31, 2025)	147 (As on Dec 31, 2023)	-
Rigel Pharmaceuticals, Inc CIN: 94‑3248524 , United States, Active	Jun 13, 1996	-	165 (As on Dec 31, 2021)	-
Rigel Pharmaceuticals Inc. CIN: 943248524 , United States, Active	Dec 26, 999	-	164 (As on Dec 31, 2024)	-

Rigel got listed on Dec 01, 2000.

Click here to take a look at Rigel's IPO in detail

Rigel has raised funding over 2 rounds. Its first funding round was on Oct 02, 2019. Its latest funding round was a Grant (prize money) round on Jan 29, 2021 for $*****. 1 investor participated in its latest round. Rigel has 8 institutional investors.

Here is the list of recent funding rounds of Rigel:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 29, 2021	3083714	Grant (prize money)	1953969	4224288	6127847	2640477
Oct 02, 2019	4855599	Conventional Debt	5073221	3207980	2467152	MidCap Financial

Access funding benchmarks and valuations. Sign up today!

View details of Rigel's funding rounds and investors

Rigel's employee count trend

Rigel has 292 employees as of Sep 26. Here is Rigel's employee count trend over the years:

Uncover Rigel's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rigel include BeiGene, Biogen and X4 Pharmaceuticals. Here is the list of Top 10 competitors of Rigel, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	X4 Pharmaceuticals 2014, Boston (United States), Public	Developer of small molecule drugs for the treatment of cancer	$58.2M	Coastlands Capital, Bain Capital Life Sciences ... & 20 others	76/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
6th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
7th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
8th	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	69/100
9th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
10th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
31st	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MidCap Financial, ProQuest Investments & 6 others	64/100